Abstract:PURPOSE: Assess incidence, severity, and glucose excursion outcomes in thyroid eye disease (TED) patients receiving the insulin-like growth factor-1 receptor inhibitor teprotumumab from 3 clinical trials.DESIGN: Analysis of pooled glycemic data over time.PARTICIPANTS: Eighty-four teprotumumab- and 86 placebo-treated active TED patients from the phase 2 and phase 3 (OPTIC) controlled clinical trials and 51 teprotumumab-treated patients from the OPTIC extension (OPTIC-X) trial.METHODS: Eight intravenous infusions were given over 21 weeks. Phase 2 serum glucose was measured at weeks 1, 4, 15, and 21, with fasting measurements at weeks 1 and 4. Serum glucose was measured at each study visit in OPTIC and OPTIC-X, with fasting measurements at weeks 1 and 4 (in patients without diabetes) or all visits (in patients with diabetes). In all studies, hemoglobin A1c (HbA1c) was measured at baseline, 12, and 24 weeks plus weeks 36 and 48 in OPTIC-X.MAIN OUTCOME MEASURES: Serum glucose and HbA1c.RESULTS: In the phase 2 and 3 studies, 9 hyperglycemic episodes occurred in 8 teprotumumab patients; mean HbA1c level increased 0.22% from baseline to week 24 (to 5.8%; range, 5.0%-7.9%) versus 0.04% in patients receiving the placebo (to 5.6%; range, 4.6%-8.1%). At study end, 78% (59/76) of teprotumumab patients and 87% (67/77) of patients receiving placebo had normoglycemic findings. Normoglycemia was maintained in 84% (57/68) of patients receiving teprotumumab and 93% (64/69) of patients receiving placebo. Among baseline prediabetic patients, 43% (3/7) remained prediabetic in both groups, and 29% (2/7) of teprotumumab patients and 14% (1/7) of patients receiving placebo had diabetic findings at week 24. OPTIC-X patients trended toward increased fasting glucose and HbA1c whether initially treated or retreated with teprotumumab. Fasting glucose commonly rose after 2 or 3 infusions and stabilized thereafter. Most hyperglycemic incidents occurred in patients with baseline prediabetes/diabetes but were controlled with medication. No evidence was found for progression or increased incidence of hyperglycemia with subsequent doses.CONCLUSIONS: Serious glycemic excursions are uncommon in patients with normoglycemia before teprotumumab therapy. Patients with controlled diabetes or impaired glucose tolerance can be treated safely if baseline screening, regular monitoring of glycemic control, and timely treatment of hyperglycemia are practiced.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

The Rate of Retreatment in Patients treated with teprotumumab: A Multicenter Study of 119 Patients with 1 year Follow Up

Teprotumumab for the treatment of chronic thyroid eye disease

Stability of Ocular Alignment After Teprotumumab Therapy in a Cohort of Patients With Thyroid Eye Disease and Baseline Diplopia

Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series

Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease

Glycemic Trends in Thyroid Eye Disease (TED) Patients Treated with Teprotumumab in 3 Clinical Trials

Teprotumumab for thyroid eye disease: early response is not required for benefit

Effects of teprotumumab and role of HLA markers in patients with thyroid eye disease

Teprotumumab for Thyroid Eye Disease-related Strabismus

Menstrual Irregularities and Amenorrhea in Thyroid Eye Disease Patients Treated With Teprotumumab

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

Outcomes of Strabismus Surgery Following Teprotumumab Therapy

Why Should We Keep Our Eyes "Wide Open"?—A Clinical and Pharmacovigilance Point of View

Teprotumumab: A Review in Thyroid Eye Disease

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment

A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System

“Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review with Meta-analysis”

1057P Long-term Follow-Up of a Phase II Study of Tislelizumab (TIS) Monotherapy in Patients (pts) with Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dmmr) Solid Tumors

Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease